Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) were down 4.3% during mid-day trading on Wednesday . The stock traded as low as $22.71 and last traded at $22.92. Approximately 50,096 shares changed hands during trading, a decline of 92% from the average daily volume of 656,643 shares. The stock had previously closed at $23.95.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Integra LifeSciences has an average rating of "Hold" and an average target price of $23.00.
Get Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Price Performance
The stock has a market capitalization of $1.73 billion, a PE ratio of -248.31, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. The stock's 50 day moving average is $23.78 and its two-hundred day moving average is $21.96. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $0.89 EPS. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.
Institutional Trading of Integra LifeSciences
A number of hedge funds have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership raised its holdings in Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after acquiring an additional 913 shares during the last quarter. KBC Group NV raised its holdings in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 1,120 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Finally, Sterling Capital Management LLC raised its holdings in Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.
About Integra LifeSciences
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
